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Discussion
Dr G. Alexander Patterson (St Louis, Mo). The distribution of
the transfection was not entirely clear to me. You showed a very
nice slide of the distribution of -Gal, and it struck me that most
of the distribution was on the epicardium, not within the cardiac
muscle itself. It seemed to me a very superficial distribution. Do
you have any immunohistochemistry or some other assay that
would allow us to know the distribution of the Adeno-ARC? Is it
the same as that of -Gal?
Dr Chatterjee. The -Gal distribution is both within the epi-
cardium and also within most of the myocardium. In terms of
Adeno-ARC expression, what we relied on was immunoblotting at
6 weeks after injection. This showed that there was a significant
increase, about a 20-fold increase in intensity, within the BZ
region of the heart.
Interestingly, when we compared Adeno-ARC expression in
the viable normal myocardium outside the infarct region, there was
only a very small increase in expression in the ARC-treated group
compared with the null controls. So, according to our immuno-
blotting at 6 weeks, there appears to be preferential localization of
Adeno-ARC within the BZ region as opposed to other regions of
the heart.
Dr Christopher A. Caldarone (Iowa City, Iowa). I was inter-
ested in the mechanism of ARC in the myocyte. You pointed out
that it worked at the level of caspase 8 and preventing release of
cytochrome C, presumably resulting in less caspase activity down-
stream. Did you make any attempt to measure caspase activity in
these specimens? The other question was in reference to the
apoptotic index.
Dr Chatterjee. In terms of measuring caspase activity, that is
a very good point. The next step in this study is looking at caspase
3 activity, as well as caspase 8 levels within our treated samples to
determine how much of a reduction occurs. In vitro evidence
demonstrates that in cell lines, injecting Adeno-ARC can block
both caspase 8 in the extrinsic pathway of apoptosis, as well as the
release of cytochrome C from the mitochondria in the intrinsic
pathway. Much of this is believed to be mediated by preventing
reactive oxygen species activity that results from ischemic injury.
In terms of your second question, the apoptotic index was the
percent of cells per high-powered field that were apoptotic. In the
control group it was about 2.7%, and in the ARC-treated group it
was 0.7%, a 4-fold reduction.
Dr Caldarone. The reason that first question might be pertinent
is because a recent study in human dilated ischemic cardiomyop-
athy demonstrated apoptosis occurring through caspase-indepen-
dent mechanisms. Therefore, I believe measuring the caspase
activity would be important.
Dr Chatterjee. Certainly. What is interesting with ARC is that
ARC has been shown to work not only in the caspase-dependent,
the death receptor-mediated pathway mediated by tumor necrosis
factor receptor 1, but also through the caspase-independent path-
way, as you mentioned, through cytochrome c. The benefit of
ARC, in theory, is that it acts on both arms of the apoptotic
cascade, and certainly in vitro evidence demonstrates a significant
reduction in downstream caspase 3 activity, the final common
pathway of apoptosis.
Dr Ralph J. Damiano, Jr (St Louis, Mo). One possibility, and
you mentioned it in your introduction, is that ARC may also have
a beneficial effect on preventing necrosis. Did you look at infarct
size in these animals, particularly in the area at risk? Was there any
effect on cell necrosis as contrasted to its primary effect on
apoptosis?
Dr Chatterjee. That is an excellent point. We have actually
looked at other anti-apoptotic agents in a similar model, and in
those groups we have seen no real change in the size of the infarct.
Our theory is that the size of the infarct is largely determined right
away in the first 24 hours; however, it really takes about 48 to 72
hours before transgene expression begins and ARC can exert a
protective effect. The acute infarct size is probably determined
before ARC is even expressed. What we do see is a small increase
in fibrosis within the BZ of the null group, suggesting that there
may be, in addition to blocking apoptosis, some antinecrosis
benefit within the BZ region of the ARC-treated group.
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